ClinicalTrials.gg
CompletedNCT00135512Updated Feb 1, 2019Results posted

Study Of 323U66 SR In Major Depressive Disorder

A Phase 2 interventional study of bupropion hydrochloride in Depressive Disorder, sponsored by GlaxoSmithKline. Completed at 7 sites in Japan. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2004, registered Aug 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
234
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Depressive Disorder by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Depressive Disorder · GlaxoSmithKline.

Enrollment
7th of 35
234 · median 33
Started
2004
with 1 other
Phase 2
6 of 39
none open now
Registered
2nd of 39
by date

Among the 39 studies in Depressive Disorder by GlaxoSmithKline, this one is the 7th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2004, is one of 6 in phase 2, and was the 2nd registered.

Depressive Disorder

856 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

None of the 39 studies in Depressive Disorder by GlaxoSmithKline is open now. The open studies under Depressive Disorder, anywhere →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies in Depressive Disorder by GlaxoSmithKline as a file.
02

Study summary

This study was designed to evaluate the efficacy and safety in major depressive disorder patients.

03

Conditions studied

  • Depressive Disorder

Browse trials for

Keywords

  • MDD
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Met criteria for major depressive disorder for their current episode for at least 8 weeks prior to screening visit.
  • Must give a written . But if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent.
  • Must have rating scores as outlined.

Exclusion criteria

Exclusion criteria:

  • Current or past history of seizure disorder or brain injury.
  • Current or past history of anorexia or bulimia nervosa.
  • History of manic episode.
  • Past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder.
  • Diagnosis of substance abuse (alcohol or drug) by the criteria.
  • Pregnant, possibly pregnant or lactating.
  • Must not be suicidal.
  • Blood pressure of SBP>160mmHg, DBP>100mmHg.
  • History or complication of cancer or malignant tumour.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
234 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases

    The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response was defined as a reduction in MADRS score from Baseline. Change from Baseline in the total score was calculated as the value at Week 8 minus the value at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 8

Secondary outcomes

  1. Change From Baseline in the MADRS Total Score at Week 52 in Observed Cases

    The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response was defined as a reduction in MADRS score from Baseline. Change from Baseline in the total score was calculated as the value at Week 52 minus the value at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 52

  2. Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Weeks 8 and 52 in Observed Cases

    Each item was rated on either a 3-point scale (0 to 2; 8 questions) or a 5-point scale (0 to 4; 9 questions), with higher scores indicating greater symptom severity. The total score was calculated by summing the individual response scores. Total score ranged from 0 to 52. The following symptoms were rated on a 5-point scale (0-4): depressed mood, low self-esteem (guilt), suicidal thoughts, work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic), anxiety (somatic), and hypochondriasis (somatization). The following symptoms were rated on a 3-point scale (0-2): insomnia (initial), insomnia (middle), insomnia (late), gastrointestinal symptoms (appetite), somatic symptoms (general), sexual disturbances, insight, and weight loss. Change from Baseline in the total score was calculated as the score at Week 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 8, 52

  3. Percentage of Participants Who Were Clinical Global Impression Global Improvement (CGI-I) Responders at Weeks 8 and 52 in Observed Cases

    The CGI-I scale was used to rate improvement in the participant's condition (benefits) since Baseline using the following 7-point scale: 1: very much improved, 2: much improved, 3: minimally improved, 4: not changed, 5: minimally worse, 6: much worse and 7: very much worse. A responder was defined as "very much improved" or "much improved".

    Time frame: Week 8, 52

  4. Change From Baseline in CGI Severity of Illness (CGI-SI) at Weeks 8 and 52 in Observed Cases

    CGI-SI was assessed on an 8-grade scale: 0, not assessed; 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill and 7, among the most extremely ill. Higher score indicated severely ill. CGI-SI was assessed by the investigator. The change from Baseline in CGI-SI score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 8, 52

  5. Change From Baseline in the Sheehan Disability Scale (SDISS) Total Score at Weeks 8 and 52 in Observed Cases

    SDISS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale. To get a total score, 3 individual scores were added and the total score ranged from "0 = unimpaired" to "30 = highly impaired". Higher scores indicate worsening. The change from Baseline in SDISS total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 8, 52

  6. Change From Baseline in the Motivation Energy Inventory Short Form (MEI-SF) Total Score at Weeks 8 and 52 in Observed Cases

    The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy and social motivation. Minimal clinically important differences were estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels and items were reverse-scored as necessary such that higher scores represent higher health-related quality of life (HRQoL) total score ranges from 0 to 108 points. Recall period was past week prior to administration. The change from Baseline in MEI-SF total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

    Time frame: Baseline (Week 0) and Week 8, 52

07

Results

Posted Feb 1, 2019

Participant flow

From 01 December 2004 to 28 May 2007, total of 234 participants with major depressive disorder were randomized at 36 centers in Japan.

Participant flow — Overall Study
MilestoneBupropion SR
Started234
Completed111
Not completed123
Withdrew: Adverse event56
Withdrew: Lack of efficacy25
Withdrew: Other42

Outcome measures

PrimaryChange From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases

The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response was defined as a reduction in MADRS score from Baseline. Change from Baseline in the total score was calculated as the value at Week 8 minus the value at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 8
Reported as:
Mean · Score on a scale
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases
Score on a scaleBupropion SR
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases-16.8 ± 8.43
SecondaryChange From Baseline in the MADRS Total Score at Week 52 in Observed Cases

The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response was defined as a reduction in MADRS score from Baseline. Change from Baseline in the total score was calculated as the value at Week 52 minus the value at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 52
Reported as:
Mean · Score on a scale
Change From Baseline in the MADRS Total Score at Week 52 in Observed Cases
Score on a scaleBupropion SR
Change From Baseline in the MADRS Total Score at Week 52 in Observed Cases-24.6 ± 8.34
SecondaryChange From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Weeks 8 and 52 in Observed Cases

Each item was rated on either a 3-point scale (0 to 2; 8 questions) or a 5-point scale (0 to 4; 9 questions), with higher scores indicating greater symptom severity. The total score was calculated by summing the individual response scores. Total score ranged from 0 to 52. The following symptoms were rated on a 5-point scale (0-4): depressed mood, low self-esteem (guilt), suicidal thoughts, work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic), anxiety (somatic), and hypochondriasis (somatization). The following symptoms were rated on a 3-point scale (0-2): insomnia (initial), insomnia (middle), insomnia (late), gastrointestinal symptoms (appetite), somatic symptoms (general), sexual disturbances, insight, and weight loss. Change from Baseline in the total score was calculated as the score at Week 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 8, 52
Reported as:
Mean · Score on a scale
Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Weeks 8 and 52 in Observed Cases
Score on a scaleBupropion SR
Week 8-11.8 ± 6.06
Week 52-17.3 ± 6.38
SecondaryPercentage of Participants Who Were Clinical Global Impression Global Improvement (CGI-I) Responders at Weeks 8 and 52 in Observed Cases

The CGI-I scale was used to rate improvement in the participant's condition (benefits) since Baseline using the following 7-point scale: 1: very much improved, 2: much improved, 3: minimally improved, 4: not changed, 5: minimally worse, 6: much worse and 7: very much worse. A responder was defined as "very much improved" or "much improved".

Time frame:
Week 8, 52
Reported as:
Number · Percentage of participant
Percentage of Participants Who Were Clinical Global Impression Global Improvement (CGI-I) Responders at Weeks 8 and 52 in Observed Cases
Percentage of participantBupropion SR
Week 868.7 (61.0 to 75.6)
Week 5289.0 (81.6 to 94.2)
SecondaryChange From Baseline in CGI Severity of Illness (CGI-SI) at Weeks 8 and 52 in Observed Cases

CGI-SI was assessed on an 8-grade scale: 0, not assessed; 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill and 7, among the most extremely ill. Higher score indicated severely ill. CGI-SI was assessed by the investigator. The change from Baseline in CGI-SI score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 8, 52
Reported as:
Mean · Score on a scale
Change From Baseline in CGI Severity of Illness (CGI-SI) at Weeks 8 and 52 in Observed Cases
Score on a scaleBupropion SR
Week 8-1.3 ± 0.98
Week 52-2.3 ± 1.16
SecondaryChange From Baseline in the Sheehan Disability Scale (SDISS) Total Score at Weeks 8 and 52 in Observed Cases

SDISS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale. To get a total score, 3 individual scores were added and the total score ranged from "0 = unimpaired" to "30 = highly impaired". Higher scores indicate worsening. The change from Baseline in SDISS total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 8, 52
Reported as:
Mean · Score on a scale
Change From Baseline in the Sheehan Disability Scale (SDISS) Total Score at Weeks 8 and 52 in Observed Cases
Score on a scaleBupropion SR
Week 8-5.0 ± 5.54
Week 52-9.7 ± 7.31
SecondaryChange From Baseline in the Motivation Energy Inventory Short Form (MEI-SF) Total Score at Weeks 8 and 52 in Observed Cases

The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy and social motivation. Minimal clinically important differences were estimated as 0.5 standard deviations or 7.5 points. All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels and items were reverse-scored as necessary such that higher scores represent higher health-related quality of life (HRQoL) total score ranges from 0 to 108 points. Recall period was past week prior to administration. The change from Baseline in MEI-SF total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline. Baseline was defined as value at Week 0.

Time frame:
Baseline (Week 0) and Week 8, 52
Reported as:
Mean · Score on a scale
Change From Baseline in the Motivation Energy Inventory Short Form (MEI-SF) Total Score at Weeks 8 and 52 in Observed Cases
Score on a scaleBupropion SR
Week 815.2 ± 15.51
Week 5226.7 ± 20.54

Adverse events

Collected over All adverse events (AE) and serious adverse events (SAE) were reported up to Week 52.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupropion SR1/233 (0.4%)14/233 (6%)210/233 (90.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBupropion SR
DepressionPsychiatric disorders3/233
Suicidal ideationPsychiatric disorders1/233
Back injuryInjury, poisoning and procedural complications1/233
Intentional misuseInjury, poisoning and procedural complications1/233
Tibia fractureInjury, poisoning and procedural complications1/233
Grand mal convulsionNervous system disorders1/233
TremorNervous system disorders1/233
Hepatic function abnormalHepatobiliary disorders1/233
Gastroenteritis bacterialInfections and infestations1/233
Spinal osteoarthritisMusculoskeletal and connective tissue disorders1/233
Most frequent other events
Most frequent other events
EventBupropion SR
NasopharyngitisInfections and infestations85/233
ThirstGeneral disorders42/233
NauseaGastrointestinal disorders26/233
HeadacheNervous system disorders22/233
DepressionPsychiatric disorders17/233
DizzinessNervous system disorders16/233
Abdominal pain upperGastrointestinal disorders14/233
ConstipationGastrointestinal disorders14/233
DiarrhoeaGastrointestinal disorders14/233
Stomach discomfortGastrointestinal disorders14/233

Baseline characteristics

Full analysis set was defined as all participants who entered treatment phase, except those who met any of the following criteria: did not satisfy the eligible disease criterion, received no dose of the investigational product and no observation data on post-treatment efficacy.

Age, Continuous
Age, Continuous(Years)Bupropion SR
Mean36.1 ± 10.13
Sex: Female, Male
Sex: Female, Male(Participants)Bupropion SR
Female101
Male131
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bupropion SR
American Indian or Alaska Native0
Asian231
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported1
08

Study locations

7 sites
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Hyogo, 651-1145, Japan
  • GSK Investigational Site
    Kanagawa, 228-0828, Japan
  • GSK Investigational Site
    Kumamoto, 861-8002, Japan
  • GSK Investigational Site
    Saitama, 332-0012, Japan
  • GSK Investigational Site
    Tokyo, 160-0023, Japan
  • GSK Investigational Site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2004 to primary completion in May 2007, 29 months.

Results were first posted in Feb 2019, 11 years 8 months after primary completion.

Of 43 phase 2 interventional studies under Depressive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2005
First posted
Aug 26, 2005
StartActual
Dec 1, 2004
Primary completionActual
May 28, 2007
CompletionActual
May 28, 2007
Results first posted
Feb 1, 2019
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00135512
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 26, 2005
Start date
Dec 1, 2004
Primary completion
May 28, 2007
Completion
May 28, 2007
Results posted
Feb 1, 2019
Last update
Feb 1, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion